A pharmaceutical test can be referred to as a clinical trial or a rigorously controlled test of a new drug or a new invasive medical device on human subjects. In the United States, it is conducted under the direction of the FDA before being made available for general clinical use. With the testing of various drugs it is important to understand their efficacy. The FDA approves drugs for the public use after said tests have gained FDA clearance. It is such a pivotal moment within the development of any drug and it costs a good amount of money to go through FDA clinical trials. Most of these trials typically involved the testing of a drug on an animal as well. Today we will analyze bioprinting and this particular sector of the healthcare industry and how it may change what is possible in years to come.
The field of pharmaceuticals focuses on the following: drug discovery as well as drug development. When one discovers a novel usage of a chemical in terms of a drug, it must then be tested thoroughly a number of times in order to have validity as a commonplace treatment to a specific pathology or ailment. This also allows for one to see how a drug may be developed in lieu of complications that arise when testing a drug. A lot of these tests can be very expensive when done. A way to reduce cost of said tests could be bioprinting. Currently, the technology is not at a scale where one can mass produce tissues or organs for the use of clinical trials on a large scale quantity. With time though, this could be a reality and it can help save time and materials for pharmaceutical companies. Bioprinting also allows pharmaceutical companies to have models of human organs that may provide more accurate test results than lets say a pig organ genetically.
We briefly have talked about animal trials already, but let us take a closer look at animal trials. Some animal tests take months or years to conduct and analyze (e.g., 4-5 years, in the case of rodent cancer studies), at a cost of a lot of dollars per substance examined (typically $2 to $4 million per two-species lifetime of a cancer study). The inefficiency and exorbitant costs associated with animal testing makes it impossible for regulators to adequately evaluate the potential effects of the more than 100,000 chemicals currently in commerce worldwide, let alone study the effects of a myriad combinations of chemicals to which humans and wildlife are exposed, at low doses, every day throughout life. One may even look into the ethics behind an animal test overall, and they could argue that bioprinting methods can be a solution to solve ethical problems of using animals detrimentally, but in a manner to serve humans. With bioprinted organs and tissue used for pharmaceutical testing animal ethics may be detracted from pharmaceutical testing (even though ethics is still very apparent if we want to analyze stem cell use within bioprinting, but that is not the topic of discussion).
Bioprinting can truly be beneficial to pharmaceutical testing if high throughput screening is also integrated. High throughput screening is a method to automate and reduce the costs of drug testing. As mentioned previously in our bioprinting series, high-throughput screening (HTS) is a method for scientific experimentation especially used in drug discovery and relevant to the fields of biology and chemistry. Using robotics, data processing/control software, liquid handling devices, and sensitive detectors, high-throughput screening allows a researcher to quickly conduct millions of chemical, genetic, or pharmacological tests. With the combination of high-throughput screening and bioprinting, automation of pharmaceutical testing will cut down the time needed to conduct these type of tests, which also leads itself to better use of time and more money to be made for pharmaceutical companies large and small.
Overall there lies large potential with bioprinting and pharmaceutical testing. It still is far from a strong reality due to the following factors:
- The healthcare industry does not innovate or change methods quickly due to the standards being used.
- A lack of FDA clearance for bioprinting as a whole holds back development
- Not a lot of work done in terms of perfecting these technologies when applied to a large scale pharmaceutical test being done
You May Also Like
Carbon Fiber Acrylonitrile Styrene Acrylate Composite (CF-ASA): New Material for Large Format Additive Manufacturing
Researchers from Spain are studying materials for more effective large-scale 3D printing, outlining their findings in the recently published ‘Development of carbon fiber acrylonitrile styrene acrylate composite for large format...
Blue Origin Opens Its New Rocket Engine Facility in Alabama
Huntsville, Alabama, is now home to Blue Origin‘s brand new rocket engine production facility, the latest addition to Huntsville’s Cummings Research Park (CRP), the second-largest research park in the United...
Focus on Improving PLA Mechanical Properties with Addition of Poly(3-Hydroxybutyrate)
In ‘Improving Mechanical Properties for Extrusion-Based Additive Manufacturing of Poly(Lactic Acid) by Annealing and blending with Poly(3-Hydroxybutyrate),’ researchers from Ghent University in Belgium, and Sichuan University in China, explore new...
High-Speed 3D Printing of Flexible Carbon/Silicone Sensors for Medical Wearables
In the recently published ‘Drop-on-demand high-speed 3D printing of flexible milled carbon fiber/silicone composite sensors for wearable biomonitoring devices,’ authors from University of Waterloo and the University of California, Berkeley...
View our broad assortment of in house and third party products.